Sequence-conditioned CogMol designs SARS-CoV-2 spike and main-protease inhibitors
IBM Research and academic collaborators used the CogMol deep generative foundation model to design compounds from target protein sequence information alone for SARS-CoV-2 spike receptor-binding domain and main protease. In vitro inhibition was reported for two of four synthesized candidates for each target; the most potent spike-RBD inhibitor also showed activity against multiple variants in live-virus neutralization assays.
Technology: CogMol, a sequence-conditioned deep generative foundation model using a molecular variational autoencoder and protein–ligand binding predictor
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In vitro inhibition was reported for two of four synthesized candidates for each target; the most potent spike-RBD inhibitor also showed activity against multiple variants in live-virus neutralization assays.
- Still unknown: The source describes a proof of concept with a small selected synthesis set from roughly 100 ranked designs. Only in-vitro target assays were performed; the leading RBD inhibitor was also tested in live-virus neutralization against variants. The paper says ADME attributes were not experimentally validated and further work is needed to confirm inhibitor binding mechanisms. These are preclinical leads, not medicines or demonstrated clinical benefit.
- AI role: The team sampled CogMol conditioned on each target's amino-acid sequence to generate candidate small molecules; candidates were filtered and ranked in silico, synthesized and assayed. The model generated compounds without target-specific fine-tuning or target-structure input at inference; assays found micromolar inhibition for 2/4 synthesized candidates for each target.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10284550/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 66 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.